Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,154 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Combination Intervention Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of an Adolescent Pregnancy Prevention Program; Relationship Smarts+ With Lessons From Mind Matters

NCT05889689
View directory record Official record
Conditions
Teen Pregnancy, Contraception Behavior, Sexually Transmitted Diseases, Reproductive Health, Sexual Risk Behavior
Interventions
Relationship Smarts Plus & Mind Matters, Relationship Smarts Plus alone, Preparing Adolescents for Young Adulthood (PAYA).
Behavioral
Lead sponsor
Trinity Church Inc.
Other
Eligibility
13 Years to 19 Years
Enrollment
945 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Exercise Program for Early Breast Cancer Survivors

NCT01140282
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
questionnaire administration, quality-of-life assessment, management of therapy complications, exercise intervention
Other · Procedure · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 30, 2026, 10:13 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

NCT02696603
View directory record Official record
Conditions
Parkinson Disease, Neurodegenerative Diseases, Movement Disorders, Central Nervous System Diseases, Brain Diseases, Basal Ganglia Diseases, Parkinsonian Disorders
Interventions
Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, Participant open-response writing, Parkinson mPower mobile application
Behavioral · Other
Lead sponsor
Sage Bionetworks
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

NCT01365156
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Adenosquamous Carcinoma, Adenocarcinoma, Locally Advanced Malignant Neoplasm, Cervical Cancer
Interventions
Extraperitoneal laparoscopic lymphadenectomy (EPLND), Chemoradiation
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Expanding the Pool in Orthotopic Heart Transplantation

NCT03222531
View directory record Official record
Conditions
Hepatitis C, Heart Transplant, Cardiac Transplant
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Mary E. Keebler, MD
Other
Eligibility
18 Years to 71 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of the Predictors and Moderators of Health Behavior Change

NCT03139656
View directory record Official record
Conditions
Health Behaviors
Interventions
Values Clarification, Planning, Combined
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 30, 2026, 10:13 AM EDT
Terminated Phase 1 Interventional

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT03422094
View directory record Official record
Conditions
Glioblastoma
Interventions
NeoVax, Nivolumab, Ipilimumab, Research blood draw, Leukapheresis for research
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Blood Flow Restriction and Exercise in Parkinson's Disease

NCT07221994
View directory record Official record
Conditions
Parkinson' Disease
Interventions
Blood flow restriction (BFR) and aerobic exercise via recumbent stepping (Nu-Step)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Treatments to Improve Smoking Cessation Medication Adherence

NCT01120704
View directory record Official record
Conditions
Smoking, Smoking Cessation, Adherence, Nicotine Dependence, Motivation
Interventions
Short Term Combination Nicotine Replacement Therapy (patch + gum), Long Term Combination Nicotine Replacement Therapy (patch + gum), Intensive Maintenance Counseling, Cognitive Medication Adherence Counseling (CAM), Electronic Medication Monitoring Device (the Helping Hand) + Feedback, Automated Adherence Prompting Phone Calls
Drug · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Fitness in Allogeneic Stem Cell Transplantation

NCT02564458
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Interval Exercise Training/Motivational Accelerometry
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 30, 2026, 10:13 AM EDT
Active, not recruiting Phase 2 Interventional

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

NCT03614949
View directory record Official record
Conditions
Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
Interventions
Stereotactic body radiation therapy (SBRT), Atezolizumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Hilliard, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Training Early Social Language in Autism

NCT03427138
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Jasper, Parent Education
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Months to 59 Months
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert

NCT00880932
View directory record Official record
Conditions
Warfarin and NSAID
Interventions
Electronic Alert
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,865 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2009 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Results available

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Durvalumab, Vicineum, Acetaminophen, Antihistamine, Bladder Biopsy, TURBT, Cystoscopy, Urine cytology, Electrocardiogram, CT, MRI
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

NCT02003209
View directory record Official record
Conditions
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
Drug · Other · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
731
States / cities
Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Terminated Phase 4 Interventional

Ticagrelor and Peripheral Arterial Disease

NCT02407314
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index, Six minute walk distance, Aspirin, Aspirin + Ticagrelor
Procedure · Device · Other + 1 more
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

NCT01999881
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
exercise intervention, standard follow-up care, quality-of-life assessment, laboratory biomarker analysis
Behavioral · Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 30, 2026, 10:13 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

NCT06295809
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Skin Neoplasms
Interventions
Pembrolizumab, Intismeran autogene, Surgery
Biological · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

OraTest in Combination With Visual Examination and Visual Examination Alone

NCT00537199
View directory record Official record
Conditions
Head And Neck Cancer, Oropharynx Cancer
Interventions
Visual Examination, OraTest
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
45 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 30, 2026, 10:13 AM EDT
Withdrawn Phase 1 Interventional

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

NCT02868632
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 30, 2026, 10:13 AM EDT
Suspended Phase 1Phase 2 Interventional

CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases

NCT05669352
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Interventions
Emavusertib, Pembrolizumab, Stereotactic Radiosurgery, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection, Biopsy Procedure, Survey Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 10:13 AM EDT
Completed Not applicable Interventional Results available

Behavioral Weight Loss and Stigma Reduction

NCT03704064
View directory record Official record
Conditions
Obesity
Interventions
Stigma-Reduction Intervention, Behavioral Weight Loss (BWL)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 30, 2026, 10:13 AM EDT
Suspended Phase 1 Interventional

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

NCT06049576
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Myrciaria dubia Prebiotic Supplement, Nivolumab
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 10:13 AM EDT